Slide 1: Immunic
{ |mmunic
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements 25 for purposes ofthesafeharbor within the meaning ofS irities Act ice statementsregardingm anagem ent’ sintentions, plans, beliefs, nsor n them. 1 kingstatement c: dl, and actual resultsmay differ materially from ing statement, whether asa result
Slide 3: Agenda: Multiple Sclerosis R&D Webcast
) Agenda: Multiple Sclerosis R&D Webcast 11:00-11:05 | Welcome and Introductions 11:05-11:10 | Vidofludimus Calcium: Mode of Action 12:30-13:00 | Featured KOL: Heinz Wiendl, MD, PhD 12:10-12:30 | Featured KOL: Lawrence Steinman, MD 13:00-13:10 | Vidofludimus Calcium: Ongoing ENSURE and CALLIPER Prog
Slide 4: Welcome and Introductions
Slide 5: Speakers: Multiple Sclerosis R&D Webcast
Speakers: Multiple Sclerosis R&D Webcast Qo Featured Key Opinion Leaders Immunic Speakers Fred D. Lublin, MD Daniel Vit, PhD. = ick f Chief Ex with Institute of Translational MBA § | ©tmmunic, inc. | Now/17/2022 & Immunic
Slide 6: Advanced Clinical Pipeline
Advanced Clinical Pipeline Three Differentiated Programs in Various Phases of Clinical Development Program | Target Preclinical [Phased Phase 2 Phase 3 Key Milestones = RiviSinterim analysis planned after approximately half) 4 of the events occurred H 1 Relapsing Multiple Sclerosis (RMS) — ENSURE Tr
Slide 7: Vidofludimus Calcium: Mode of Action
Slide 8: Vidofludimus Calcium Selectively Targets Only Hyperactive Immune Cells
Vidofludimus Calcium Selectively Targets Only Hyperactive Immune Cells Lymphocyte Activated “Stressed” Lymphocyte Insufficient CY) pyrimidine recycling IMU-838 e | Se as ae \ Gbnnbor Vyr® ——q“~ Disease related se activation Pharmacological Lymphocyte Effects Matabolically silent Activation of pyrimi
Slide 9: Vidofludimus Calcium: Phase 2 EMPhASIS Trial in RRMS
Slide 10: EMPhASIS Trial: Phase 2 Study Overview in RRMS
EMPhASIS Trial: Phase 2 Study Overview in RRMS NCT03846219 Included Patient Population: RRMS With Relevant Disease Activity = Male or female (182 age <55) ‘ Coordinating Investigator = RRMS diagnosis (Revised McDonald criteria 2017) = Evidence of disease activity based on relapse and MRI criteria Ro
Slide 11: EMPhASIS Trial: Phase 2 Trial Design in RRMS
EMPhASIS Trial: Phase 2 Trial Design in RRMS Screening upto Main treatment period Extended treatment period up to 28days* 2dweeks 9.5 years (optional nde ae T jeag 300r45 me 30 mgIMU-838 — EoMT 30 mg IMU-838 Uae cor 300r.45 me 45 mgiMU-838 — EoMT ———45mgiMu-838 — 02°" 0 — gor Ser. BLMRI ernie or45 m
Slide 12: EMPhASIS Trial: Strong Reduction of MRI Lesion Activity
EMPhASIS Trial: Strong Reduction of MRI Lesion Activity Primary Endpoint Hit With High Significance, Pooled Cohorts 1 & 2 Vidofludimus calcium showed strong activity on primary study endpoint in phase 2 trial = Double-blind, placebo-controlled, randomized, parallel- group phase 2 trial in RRMS = Bli
Slide 13: EMPhASIS Trial: Highly Significant MRI Lesion Suppression
EMPhASIS Trial: Highly Significant MRI Lesion Suppression eee Compares Favorably to Other First-Line and Oral Base Medications Commercially Available in RRMS* Vidofludimus. Vidofludimus. Glatiramer Dimethyl ' (21 1 is] Calaium Glcum Acetate Teriflunomide' Fumarate! Fingolimod Ozanimod' Administratio
Slide 14: EMPhASIS Trial: Reduction of Serum NfL Concentrations Observed
EMPHASIS Trial: Reduction of Serum NfL Concentrations Observed Versus Placebo After 24 Weeks, Pooled Cohorts 1 & 2 50% Vidofludimus calcium showeda [ remarkable reduction in NfL levels in all active doses tested compared with placebo = The relative change of serum Nfl versus placebo is proportional
Slide 15: Reduction of Serum NfL by Vidofludimus Calcium
Reduction of Serum NfL by Vidofludimus Calcium Similar to Effect Size Shown by Ocrelizumab Versus Baseline 45 mg vidofludimus calcium Ocrelizurnab, OBOE phase 3 trial 0.0% RES EaRGeS Vidofludimus calcium showeda strong impact on serum NfL consistent with results shown by market leader, ocrelizumab,
Slide 16: New Data From Phase 2 EMPhASIS Trial in RRMS
Immunic . C ( « THERAPEUTICS New Data From Phase 2 EMPhASIS Trial in RRMS Interim Analysis of Open-Label Extension (OLE) Phase
Slide 17: Interim Analysis of EMPhASIS Trial: Long-Term Exposure Data
Interim Analysis of EMPhASIS Trial: Long-Term Exposure Data Low Rate of Treatment Discontinuations During Long-Term Extension Treatment Total Number of Patients* Randomized 269 Started Blinded Treatment 268 Discontinued Blinded Treatment 14 Completed Blinded Treatment (Week 24) 254 Started Open-Labe
Slide 18: Disease Course of Relapsing and Progressive Multiple Sclerosis
Disease Course of Relapsing and Progressive Multiple Sclerosis felapsing MS Progatve MS a ® & g | ‘ = eps z ‘ i] 3 2 Fora life-long disease such IN as multiple sclerosis, patients MARS le «eee ee 0 «6 @ 5 0 : require safe treatments to TIME year) Ont 5 0 5 » | : avoid or delay accumulating s | r, di
Slide 19: Emerging Data Support a Change in Thinking About What is Driving Long-Term Patient Outcomes
Emerging Data Support a Change in Thinking About What is Driving Long-Term Patient Outcomes in Relapsing and Progressive MS = New data validates that relapse- independent worsening is responsible for ~50% of disability worsening in the relapsing phase of MS, and 100% in the progressive phase of MSU.
Slide 20: EMPhASIS Trial: Encouraging Signals of Unconfirmed EDSS Changes
EMPhASIS Trial: Encouraging Signals of Unconfirmed EDSS Changes Based on Pooled Cohort 1 & 2 Data Mean Change of EDSS from Baseline to Week 24 Proportion of Patients With Unconfirmed EDSS Progression up to Week 24 a Percent 2 25 ~ (WALUERS : — 45 26 __— _ ret [VALUE (VALUES 40 25 5 24 Week 12 Week 2
Slide 21: EMPhASIS Trial: Measurement of Confirmed Disability Worsening (CDW) Events
EMPhASIS Trial: Measurement of Confirmed Disability Worsening (CDW) Events BL “Trigger Event” Confirmation Event’ Increase in EDSS compared to baseline of at least 1.5 Atthe confirmation event and each assessment between points if baseline EDSS = 0, of at least 1.0 points if baseline trigger and pos
Slide 22: EMPhASIS Trial: Confirmed Disability Worsening Events
EMPhASIS Trial: Confirmed Disability Worsening Events End of 24-Week Blinded Treatment Period CDW Events at the End of the 24-Week Blinded Treatment Period 4.0% ane 5% Data confirm a signal in ave preventing 12-week and 24- ne week confirmed disability worsening events as compared to placebo. 1.6% 1
Slide 23: EMPhASIS Trial: Interim Analysis Regarding 24-Week CDW Events
EMPhASIS Trial: Interim Analysis Regarding 24-Week CDW Events Patients Free of 24-Week CDW After 1 and 2 Years of OLE Vidofludimus Calcium Treatment Pro nof Patients Free From 24-Week irmed Disability V ung 94.5% —> Data confirm that only a few patients on continuous treatment with vidofludimus calc
Slide 24: 12-Week Confirmed Disease Worsening after 2 Years (96 Weeks)
12-Week Confirmed Disease Worsening after 2 Years (96 Weeks) EMPhASIS Data from OLE Interim Analysis 2022 Compared to Examples from Historical Trials 6 of Patients at Risk} onfirmed Disability Worsening week/3-Months C RRMS SPMS 13.6% [VALUE] OPERA EXPAND EXPAND Placebo Patients with 1 [VALUE] [VALU
Slide 25: 24-Week Confirmed Disease Worsening after 2 Years (96 Weeks)
24-Week Confirmed Disease Worsening after 2 Years (96 Weeks) EMPhASIS Data from OLE Interim Analysis 2022 Compared to Examples from Historical Trials Patients with 24-Week/6-Month firmed D bility Wo. f Patients at Risk) RRMS SPMS [VALUE] [VALUE] 10% [VALUE] E [VALUE] 10.5% [VALUE] EMPhASIS OPTIMUM —
Slide 26: Immunic Therapeutics
THERAPEUTICS
Slide 27: New Understanding of Drivers of Long-Term Patient Outcomes
New Understanding of Drivers of Long-Term Patient Outcomes First Key Publication in 2022 El Most Disease Progression is Independent of Relapse, Even in Early RMS"! = Longstanding belief that the disability worsening process is only driven by relapse activity in RMS Patients = New analysis of 35,000+
Slide 28: Vidofludimus Calcium: Antiviral Data
Slide 29: Featured KOL: Lawrence Steinman, MD
Slide 30: Link of Epstein-Barr Virus (EBV) Infection and Onset of MS
Link of Epstein-Barr Virus (EBV) Infection and Onset of MS Fig. 3. EBV infection precedes. levation of sNFL before the onset ‘of MS. (A) Box plots of si levels before, around, and after the time of EBV infection. *P < 005, two sided mutivaiabe near regression mode! adjusted for age and sex. (B) With
Slide 31: Epstein-Barr Virus (EBV) Antibody Titers are Higher in MRI-Active Patients
Epstein-Barr Virus (EBV) Antibody Titers are Higher in MRI-Active Patients oO iw) | 205 | 4000 p<0.001 p<0.001 & = 2 154 S 3000} s ° ee 2. 2 . S10 = 2000+ oO & 791 % 40004 | s $8 S 295 « BD 0 = ° 04 © EBNA-1Gd-ve EBNA-1 Gd +ve Ratio Gd-ve Ratio Gd +ve Subjects with non-active/active MRI Subjects wit
Slide 32: EBV Virus Shedding in Saliva as Indicator for Lytic Infection
Epstein-Barr Virus (EBV) Virus Shedding in Saliva as Indicator for Lytic (Active) Infection Lytic EBV Activityin an MS Population Teriflunomide Decreases Lytic EBV Activity Number of Overall Proportion of Patients Samples With EBV Shedding? Studies Patients with EBV with EBV Virus Shedding x Sheddin
Slide 33: Vidofludimus Calcium: DHODH Inhibition Provides Broad-Spectrum Antiviral Activity
Vidofludimus Calcium: DHODH Inhibition Provides Broad- Spectrum Antiviral Activity Against Different Pathogenic Viruses Antiviral Activity With EC., Values in Single Digit uM Range = Viruses rely on the host cell’s infrastructure for a oy replication g aie = Inhibition of DHODH by vidofludimus calci
Slide 34: Prevention of EBV Reactivation by Vidofludimus Calcium
Prevention of Epstein-Barr Virus (EBV) Reactivation by Vidofludimus Calcium Theorized to Provide Long-Term Benefit for MS Patients Direct Antiviral Effect: Blocks EBV Replication, Reactivation and Virus Particle Production = With each reactivation and infection cycle, a newly generated patna - humor
Slide 35: Vidofludimus Calcium: Potent Anti-EBV Activity Demonstrated in Cell-Culture-Based Systems
Vidofludimus Calcium: Potent Anti-Epstein-Barr Virus (EBV) Activity Demonstrated in Cell-Culture-Based Systems Anti-Akata-BX1-EBV-GFP stimulated with higG lyticreactivation of EBV strongly is reduced by Vidofludimus calcium 110 100 =a aii BO5-8 Zz 20. 2 80 A5- 20- = a = = = 7 Ew = = 50 = 8 S 2 a SuM
Slide 36: Hints for Clinical Anti-SARS-CoV-2 Activity and Maintaining Humoral Response
Vidofludimus Calcium Showed Interesting Hints for Clinical Anti-SARS-CoV-2 Activity and Maintaining Humoral Response Treatment Corresponds with Decreased @ Treatment Does Not Interfere With Antibody 35% 20% 2 25% Ee 2% OE SE ise Pe i 10% 59% ov mi lomg IMU-838. Number of Opportunistic SARS-CoV-2 Inf
Slide 37: New Understanding of Drivers of Long-Term Patient Outcomes: Role of EBV
New Understanding of Drivers of Long-Term Patient Outcomes More Key Publications in 2022 Regarding Role of Epstein-Barr Virus Epstein-Barr Virus (EBV) is Essential for Onset of MS and Involved in Ongoing Autoimmunity"2) = Epidemiologic study showed a clear association between EBV infection and occur
Slide 38: Featured KOL
Slide 39: Ongoing Epstein-Barr Virus (EBV) Infection During the MS Course
Ongoing Epstein-Barr Virus (EBV) Infection During the MS Course System in MS Patients EBV Infection and Reactivation Seems to be an Ongoing Trigger for the Immune = MS is not only preceded by EBV infection, but also associated with broader EBV-specificT cell receptor repertoires, consistent with an
Slide 40: tN
tN
Slide 41: Q&A Session
Slide 42: Vidofludimus Calcium: Ongoing ENSURE and CALLIPER Programs
Slide 43: Straightforward Approval Strategy in Multiple Sclerosis
Straightforward Approval Strategy in Multiple Sclerosis Enables Clear Demonstration of Effect on Smoldering MS Phase 3 ENSURE Program in RMS"I Phase 2 CALLIPER Trial in PMS?! = Phase 2 trial in PMS patients = Goal: Demonstrate vidofludimus calcium’s potential for neuroprotective activity in a non-re
Slide 44: ENSURE Program: Ongoing Pivotal Phase 3 Trials in RMS
ENSURE Program: Ongoing Pivotal Phase 3 Trials in RMS NCT05134441 & NCT05201638 Two Multicenter, Randomized, Double-Blind Phase 3 Trials - = Approximately 1,050 patients in each trial . Coordinating Investigator = More than LOO sites in the United States, Latin America, Central and Eastern Europe, a
Slide 45: CALLIPER Trial: Ongoing Phase 2 Trial Intended to Complement the Phase 3 Program in RMS
CALLIPER Trial: Ongoing Phase 2 Trial Intended to Complement the Phase 3 Program in RMS il Multicenter, Randomized, Double-Blind, = Placebo-Controlled Phase 2 Trial* = Approximately 450 patients in more than 70 sites in North Ny Coordinating Investigator America, Western, Central and Eastern Europe
Slide 46: Straightforward Path Towards Potential Approval
Straightforward Path Towards Potential Approval CALLIPER Interim Analysis 2/2023 CALLIPER Readout End of 2024 ENSURE-1 Readout End of 2025 ENSURE-2 Readout 2026 NDA Submission 2026 H1 H2 H1 H1 2024 2025 2026 RMSENSURE-1—Phase 3 PMS CALLIPER ~ Phase 2 RMSENSURE-2—- 2" Phase 3 ‘These timelines are cur
Slide 47: Vidofludimus Calcium: Strategy and Positioning
Slide 48: Majority of Patients with MS Have a Very Low Risk Tolerance for Safety Issues of DMTs
Publication Highlights That the Majority of Patients with MS Have a Very Low Risk Tolerance for Safety Issues of DMTs ens] NARCCOMS | ‘North American Research Committee on Multiple Sclerosis A survey of risk tolerance to multiple sclerosis therapies Fox Fl, CozenaaC, Cripps, FordP, Marcar,Hstarsan S
Slide 49: Claims Analysis: Significant Proportion of MS Patients Prioritizes Safety Over Efficacy
Claims Analysis Also Evidences That Significant Proportion of the MS Patient Population Prioritizes Safety Over Efficacy Claims Analysis Over Most Recent Three Years Percent of Patients Exposed to Each DMT = Despite only 34% prevention of relapses at two years, glatiramer acetate is the = Patient ch
Slide 50: Vidofludimus Calcium Addresses Multiple Drivers of Neurodegeneration in MS Patients
Vidofludimus Calcium Addresses Multiple Drivers of Neurodegenerationin MS Patients Bi anti-virar Effects f Vidofludimus calcium can Broad-spectrum antiviral activity established v EBV linked to MS Y Vidofludimus calcium target various aspects of ‘smoldering’ MS with potent anti-EBV activity Direct N
Slide 51: The Unmet Needs in MS Encompasses Multiple Patient Segments
The Unmet Needs in MS Encompasses Multiple Patient Segments 725,000 Us diagnosed MS patients”) Multiple opportunities to address unmet needs of patients B28 Untreated patients oneeea Patients with am va rogressive di Patientswho need pe ee alternatives Address disability rogression L [ ib Risk intol
Slide 52: Vidofludimus Calcium Aimed to Go Above and Beyond Current Care
Vidofludimus Calcium Aimed to Go Above and Beyond Current Care to Comprehensively Address Patients’ Needs Targeted to elevate the standard of care with a holistic solution for MS patients Uniquely matched to the multi-faceted neurodegeneration of smoldering and active MS = Anti-viral effects = Anti-
Slide 53: Q&A Session and Closing
Slide 54: Thank You!
Thank You! Head of IR & Communications Phone: +49-89-2080477-09 Email: ir@imux.com Web: www.imux.com 54 | ©tmmunic, ino. | Now/t7/2022 Immunic, Ine. 1200 Avenue of the Americas New York City, NY 10036 USA Immunic AG Lochhamer Schlag 21 82.166 Grifelfing (Munich) Germany Immunic Australia Pty. Ltd. M
Slide 55: Back-up
Slide 56: EMPhASIS Trial: Interim Analysis Regarding 12-Week CDW Events
EMPhASIS Trial: Interim Analysis Regarding 12-Week CDW Events Patients Free of 12-Week CDW After 1 and 2 Years of OLE Vidofludimus Calcium Treatment Proportion o 12-week firmed disability worsening 94.1% —e Data confirm that only a few patients on continuous treatment with vidofludimus calcium devel
Slide 57: 12-Week Confirmed Disease Worsening after 1 Year (48 Weeks)
12-Week Confirmed Disease Worsening after 1 Year (48 Weeks) EMPhASIS Data from OLE Interim Analysis 2022 Compared to Examples from Historical Trials with 12-Week Confirmed Disability Worsening (% of Pati nts at Ris RRMS SPMS = [VALUE] = [VALUE] = [VALUE] SALUEI 6.6% [VALUE] EMPhASIS OPTIMUM —ASCLEPI
Slide 58: 24-Week Confirmed Disease Worsening after 1 Year (48 Weeks)
24-Week Confirmed Disease Worsening after 1 Year (48 Weeks) EMPhASIS Data from OLE Interim Analysis 2022 Compared to Examples from Historical Trials Patients with 24-Week Confirmed Di bility Worsening (% of Patients at Ris 30% RRMS SPMS. 20% [VALUE] = [VALUE] 10% = [VALUE] = [VALUE] =[VALL Nae) (VAL